In Brief: Abbott/SpectRx
This article was originally published in The Gray Sheet
Executive Summary
Abbott/SpectRx: Diagnostic firms are conducting "developmental studies" of a non-invasive monitor to measure glucose in interstitial fluid. The Jan. 19 "Gray Sheet" reported that pivotal trials for the device would commence in 1998. SpectRx still expects Abbott to submit a 510(k) for the device sometime in 1999, the company says...